MannKind

Price & Volume

Track all markets on TradingView

Stats

See more
52W Range
$2.23-$6.51
Market Cap
$1B
Shares Short
29M

Financials

See more
Revenue (12 Mos)
$360.7M
Revenue Growth (YoY)
15.1%
Gross Profit (12 Mos)
$272.8M
Diluted EPS
-$0.07

News

See more

Yahoo Finance • 2 days ago

Mankind: Afreezza Data At ADA 2026 Underscores Pediatric Safety And Expands Use In Diabetes Care

Yahoo Finance • 5 days ago

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Yahoo Finance • 12 days ago

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

Yahoo Finance • 12 days ago

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

About

CEO
Dr. Michael E. Castagna Pharm.D.
Address
1 Casper Street, Danbury, CT, United States, 06810
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
591